The metabolic basis of kidney cancer

Seminars in Cancer Biology

Volumn 23, Issue 1, 2013, Pages 46-55

  Linehan, W Marston ^a   Ricketts, Christopher J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer metabolism; Cancer metabolism targeted therapy; Hereditary kidney cancer; Renal cell carcinoma (RCC); Warburg effect

Indexed keywords

ALPHA INTERFERON; APOPTOSIS SIGNAL REGULATING KINASE 1; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; FUMARATE HYDRATASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; SCATTER FACTOR; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR; TRICARBOXYLIC ACID; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; BIRT HOGG DUBE SYNDROME; COMPLEX II DEFICIENCY; COWDEN SYNDROME; DISEASE ASSOCIATION; DRUG TARGETING; EAR TUMOR; ENDOLYMPHATIC SAC TUMOR; ENZYME DEFICIENCY; FH GENE; FLCN GENE; FUMARATE HYDRATASE DEFICIENCY; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEREDITARY LEIOMYOMATOSIS RENAL CELL CARCINOMA; HEREDITARY PAPILLARY RENAL CARCINOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY HEMANGIOMYOLIPOMA; KIDNEY METASTASIS; KIDNEY TUMOR; LINKAGE ANALYSIS; MET GENE; METABOLIC DISORDER; MITF GENE; NONHUMAN; OXYGEN SENSING; PTEN GENE; REVIEW; RISK FACTOR; SHDB GENE; TFE3 GENE; TFEB GENE; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; VHL GENE; VON HIPPEL LINDAU DISEASE;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CITRIC ACID CYCLE; HUMANS; KIDNEY NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84873079111     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.06.002     Document Type: Review

References (94)

1. Linehan W.M., Walther M.M., Zbar B. The genetic basis of cancer of the kidney. Journal of Urology 2003, 170:2163-2172.
2. Linehan W.M., Srinivasan R., Schmidt L.S. The genetic basis of kidney cancer: a metabolic disease. Nature Reviews Urology 2010, 7:277-285.
3. Lonser R.R., Glenn G.M., Walther M.M., Chew E.Y., Libutti S.K., Linehan W.M., et al. von Hippel-Lindau disease. Lancet 2003, 361:2059-2067.
4. Wong W.T., Agron E., Coleman H.R., Reed G.F., Csaky K., Peterson J., et al. Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Archives of Ophthalmology 2007, 125:239-245.
5. Filling-Katz M.R., Choyke P.L., Oldfield E., Charnas L., Patronas N.J., Glenn G.M., et al. Central nervous system involvement in von Hippel-Lindau disease. Neurology 1991, 41:41-46.
6. Choo D., Shotland L., Mastroianni M., Glenn G., van W.C., Linehan W.M., et al. Endolymphatic sac tumors in von Hippel-Lindau disease. Journal of Neurosurgery 2004, 100:480-487.
7. Choyke P.L., Glenn G.M., Wagner J.P., Lubensky I.A., Thakore K., Zbar B., et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997, 49:926-931.
8. Libutti S.K., Choyke P.L., Bartlett D.L., Vargas H., Walther M., Lubensky I., et al. Pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease: diagnostic and management recommendations. Surgery 1998, 124:1153-1159.
9. Blansfield J.A., Choyke L., Morita S.Y., Choyke P.L., Pingpank J.F., Alexander H.R., et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). Surgery 2007, 142:814-818.
10. Poston C.D., Jaffe G.S., Lubensky I.A., Solomon D., Zbar B., Linehan W.M., et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. Journal of Urology 1995;153:22-6.
11. Xia W., Nagase S., Montia A.G., Kalachikov S.M., Keniry M., Su T., et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Research 2008, 68:1667-1674.
12. Pedersen M.T., Helin K. Histone demethylases in development and disease. Trends in Cell Biology 2010, 20:662-671.
13. Varier R.A., Timmers H.T. Histone lysine methylation and demethylation pathways in cancer. Biochimica et Biophysica Acta 2011, 1815:75-89.
14. Young A.P., Schlisio S., Minamishima Y.A., Zhang Q., Li L., Grisanzio C., et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nature Cell Biology 2008, 10:361-369.
15. Welford S.M., Dorie M.J., Li X., Haase V.H., Giaccia A.J. Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Molecular and Cellular Biology 2010, 30:4595-4603.
16. Niu X., Zhang T., Liao L., Zhou L., Lindner D.J., Zhou M., et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 2012, 31:776-786.
17. Kaelin W.G. von Hippel-Lindau disease. Annual Review of Pathology: Mechanisms of Disease 2007, 2:145-173.
18. Semenza G.L. Oxygen sensing, homeostasis, and disease. New England Journal of Medicine 2011, 365:537-547.
19. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer 2002, 2:673-682.
20. Li L., Zhang L., Zhang X., Yan Q., Minamishima Y.A., Olumi A.F., et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Molecular and Cellular Biology 2007, 27:5381-5392.
21. Clifford S., Cockman M., Smallwood A., Mole D., Woodward E., Maxwell P., et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Human Molecular Genetics 2001, 10:1029-1038.
22. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., Kaelin W.G. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Molecular Genetics 2001, 10:1019-1027.
23. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell 2008, 30:393-402.
24. Makino Y., Kanopka A., Wilson W.J., Tanaka H., Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. Journal of Biological Chemistry 2002, 277:32405-32408.
25. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001, 414:550-554.
26. Maynard M.A., Evans A.J., Hosomi T., Hara S., Jewett M.A., Ohh M. Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB Journal 2005, 19:1396-1406.
27. Maynard M.A., Qi H., Chung J., Lee E.H., Kondo Y., Hara S., et al. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. Journal of Biological Chemistry 2003, 278:11032-11040.
28. 2 sensing. Science 2001, 292:464-468.
29. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
30. Yu F., White S., Zhao Q., Lee F. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9630-9635.
31. Epstein A., Gleadle J., McNeill L., Hewitson K., O'Rourke J., Mole D., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
32. Bruick R., McKnight S. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
33. Ivan M., Haberberger T., Gervasi D.C., Michelson K.S., Gunzler V., Kondo K., et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:13459-13464.
34. Kim W.Y., Safran M., Buckley M.R., Ebert B.L., Glickman J., Bosenberg M., et al. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO Journal 2006, 25:4650-4662.
35. Liu Y.V., Baek J.H., Zhang H., Diez R., Cole R.N., Semenza G.L. RACK1 competes with HSP90 for binding to HIF-1α and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Molecular Cell 2007, 25:207-217.
36. Ornstein D.K., Lubensky I.A., Venzon D., Zbar B., Linehan W.M., Walther M.M. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. Journal of Urology 2000, 163:431-433.
37. Schmidt L.S., Duh F.M., Chen F., Kishida T., Glenn G.M., Choyke P., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics 1997, 16:68-73.
38. Schmidt L.S., Nickerson M.L., Angeloni D., Glenn G.M., Walther M.M., Albert P.S., et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene. Journal of Urology 2004, 172:1256-1261.
39. Esteve-Puig R., Canals F., Colome N., Merlino G., Recio J.A. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS ONE 2009, 4:e4771.
40. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes and Development 2009, 23:537-548.
41. Srinivasan R., Choueiri T.K., Vaishampayan U., Rosenberg J.E., Stein M.N., Logan T., et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). Journal of Clinical Oncology 2008, 26(May (Suppl.)):5103.
42. Birt A.R., Hogg G.R., Dube W.J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Archives of Dermatology 1977, 113:1674-1677.
43. Toro J.R., Pautler S.E., Stewart L., Glenn G.M., Weinreich M., Toure O., et al. Lung cysts, spontaneous pneumothrorax and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. American Journal of Respiratory and Critical Care Medicine 2007, 175:1044-1053.
44. Zbar B., Alvord W.G., Glenn G.M., Turner M., Pavlovich C.P., Schmidt L.S., et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiology, Biomarkers and Prevention 2002, 11:393-400.
45. Pavlovich C.P., Walther M.M., Eyler R.A., Hewitt S.M., Zbar B., Linehan W.M., et al. Renal tumors in the Birt-Hogg-Dubé syndrome. American Journal of Surgical Pathology 2002, 26:1542-1552.
46. Nickerson M.L., Warren M.B., Toro J.R., Matrosova V., Glenn G.M., Turner M.L., et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2002, 2:157-164.
47. Toro J.R., Wei M.H., Glenn G.M., Weinreich M., Toure O., Vocke C.D., et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. Journal of Medical Genetics 2008, 45:321-331.
48. Vocke C.D., Yang Y., Pavlovich C.P., Schmidt L.S., Nickerson M.L., Torres-Cabala C.A., et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. Journal of the National Cancer Institute 2005, 97:931-935.
49. Baba M., Hong S.B., Sharma N., Warren M.B., Nickerson M.L., Iwamatsu A., et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:15552-15557.
50. Hasumi H., Baba M., Hong S.B., Hasumi Y., Huang Y., Yao M., et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 2008, 415:60-67.
51. Hasumi Y., Baba M., Ajima R., Hasumi H., Valera V.A., Klein M.E., et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:18722-18727.
52. Baba M., Furihata M., Hong S.B., Tessarollo L., Haines D.C., Southon E., et al. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. Journal of the National Cancer Institute 2008, 100:140-154.
53. Malouf G.G., Camparo P., Molinie V., Dedet G., Oudard S., Schleiermacher G., et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. Journal of Urology 2011, 185:24-29.
54. Shipley J.M., Birdsall S., Clark J., Crew J., Gill S., Linehan W.M., et al. Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case. Cytogenetics and Cell Genetics 1995, 71:280-284.
55. Sidhar S.K., Clark J., Gill S., Hamoudi R., Crew J., Gwilliam R., et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 tanscription factor gene. Human Molecular Genetics 1996, 5:1333-1338.
56. Weterman M.A., Wilbrink M., Janssen I., Janssen H.A., Van Den B.E., Fisher S.E., et al. Molecular cloning of the papillary renal cell carcinoma-associated translocation (X;1)(p11;q21) breakpoint. Cytogenetics and Cell Genetics 1996, 75:2-6.
57. Clark J., Lu Y.J., Sidhar S.K., Parker C., Gill S., Smedley D., et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997, 15:2233-2239.
58. Argani P., Hicks J., De Marzo A.M., Albadine R., Illei P.B., Ladanyi M., et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. American Journal of Surgical Pathology 2010, 34:1295-1303.
59. Zhong M., De A.P., Osborne L., Keane-Tarchichi M., Goldfischer M., Edelmann L., et al. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. American Journal of Surgical Pathology 2010, 34:757-766.
60. Argani P., Antonescu C.R., Couturier J., Fournet J.C., Sciot R., Debiec-Rychter M., et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). American Journal of Surgical Pathology 2002, 26:1553-1566.
61. Armah H.B., Parwani A.V. Xp11.2 translocation renal cell carcinoma. Archives of Pathology & Laboratory Medicine 2010, 134:124-129.
62. Argani P., Hawkins A., Griffin C.A., Goldstein J.D., Haas M., Beckwith J.B., et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. American Journal of Pathology 2001, 158:2089-2096.
63. Davis I.J., Hsi B.L., Arroyo J.D., Vargas S.O., Yeh Y.A., Motyckova G., et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:6051-6056.
64. Maubec E., Chaudru V., Mohamdi H., Grange F., Patard J.J., Dalle S., et al. Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer 2010, 116:5716-5724.
65. Bertolotto C., Lesueur F., Giuliano S., Strub T., de L.M., Bille K., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011.
66. Cheli Y., Ohanna M., Ballotti R., Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell and Melanoma Research 2010, 23:27-40.
67. Malouf G.G., Camparo P., Oudard S., Schleiermacher G., Theodore C., Rustine A., et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Annals of Oncology 2010, 21:1834-1838.
68. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. New England Journal of Medicine 2006, 355:1345-1356.
69. Bjornsson J., Short M.P., Kwiatkowski D.J., Henske E.P. Tuberous sclerosis-associated renal cell carcinoma clinical, pathological, and genetic features. American Journal of Pathology 1996, 149:1-8.
70. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., Kaelin W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4:147-158.
71. Brugarolas J., Kaelin W.G. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 2004, 6:7-10.
72. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New England Journal of Medicine 2008, 358:140-151.
73. Gustafson S., Zbuk K.M., Scacheri C., Eng C. Cowden syndrome. Seminars in Oncology 2007, 34:428-434.
74. Blumenthal G.M., Dennis P.A. PTEN hamartoma tumor syndromes. European Journal of Human Genetics 2008, 16:1289-1300.
75. Eng C. PTEN: one gene, many syndromes. Human Mutation 2003, 22:183-198.
76. Squarize C.H., Castilho R.M., Gutkind J.S. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Research 2008, 68:7066-7072.
77. Warburg O., Posener K., Negelein E. Metabolism of the carcinoma cell. Biochemische Zeitschrift 1924, 152:309-344.
78. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
79. Launonen V., Vierimaa O., Kiuru M., Isola J., Roth S., Pukkala E., et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:3387-3392.
80. Zbar B., Glenn G.M., Lubensky I.A., Choyke P., Magnusson G., Bergerheim U., et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. Journal of Urology 1995, 153:907-912.
81. Toro J.R., Nickerson M.L., Wei M.H., Warren M.B., Glenn G.M., Turner M.L., et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. American Journal of Human Genetics 2003, 73:95-106.
82. Merino M.J., Torres-Cabala C., Pinto P.A., Linehan W.M. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. American Journal of Surgical Pathology 2007, 31:1578-1585.
83. Grubb R.L., Franks M.E., Toro J., Middelton L., Choyke L., Fowler S., et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. Journal of Urology 2007, 177:2074-2080.
84. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genetics 2002, 30:406-410.
85. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
86. Tong W.H., Sourbier C., Kovtunovych G., Jeong S.Y., Vira M., Ghosh M., et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases metabolic propensities and lowers cellular iron levels. Cancer Cell 2011, 20:315-327.
87. Yang Y., Valera V.A., Padilla-Nash H.M., Sourbier C., Vocke C.D., Vira M.A., et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics 2010, 196:45-55.
88. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
89. Niemann S., Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics 2000, 26:268-270.
90. Eng C., Kiuru M., Fernandez M.J., Aaltonen L.A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Reviews Cancer 2003, 3:193-202.
91. Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004, 292:943-951.
92. Vanharanta S., Buchta M., McWhinney S.R., Virta S.K., Peczkowska M., Morrison C.D., et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. American Journal of Human Genetics 2004, 74:153-159.
93. Ricketts C., Woodward E.R., Killick P., Morris M.R., Astuti D., Latif F., et al. Germline SDHB mutations and familial renal cell carcinoma. Journal of the National Cancer Institute 2008, 100:1260-1262.
94. Henderson A., Douglas F., Perros P., Morgan C., Maher E.R. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Familial Cancer 2009, 8:257-260.